Last reviewed · How we verify
NCT04501159: pHHd
pH, Hypoxia and Haemodialysis
trial testing blood sample pre, during and post HD in End Stage Renal Disease on Dialysis in 100 participants. Status unknown.
21 August 2021
Quick facts
| Lead sponsor | Coventry University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 May 2021 |
| Primary completion | 21 August 2021 |
| Estimated completion | 29 December 2021 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- blood sample pre, during and post HD
- Non invasive cardiac output assessment
Conditions studied
- End Stage Renal Disease on Dialysis — all drugs for End Stage Renal Disease on Dialysis →
Sponsor
Coventry University
Who can join
18 and older, any sex, with End Stage Renal Disease on Dialysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
End-stage renal disease typically requires haemodialysis to help replace kidney function. However, changes in oxygen uptake during haemodialysis have been linked to increased all-cause mortality. This complication of haemodialysis is linked to decreasing fluid volume, compromising blood flow to tissue and leukostasis within pulmonary tissue. However, an alternative cause of reduced oxygen availability (hypoxia) during haemodialysis is acute alkalosis. Alkalosis during haemodialysis can cause hypoxia via dysregulated ventilation and impaired ability for tissue to extract oxygen. Despite strong rationale for these mechanisms, few studies have fully explored causes of hypoxia during haemodialysis. Greater understanding may help to mitigate the risk associated with this vital treatment option. The study will comprise of end-stage renal disease patients who regularly undergo haemodialysis. Three blood samples will be attained before, during and after haemodialysis to assess arterial blood gases. In a small subset of patients, white blood cell (WBC) count and cardiac output will be assessed via a non-invasive cardiac output monitor during treatment. Regression analysis will be performed to help identify predictors of hypoxia during haemodialysis. Patient burden is negligible, with blood samples attained from the dialyser as part of routine treatment. In the patients who agree for cardiac output assessment, the patient will be required to have four small noninvasive sensor pads placed on the chest. Patients will be assessed over 3 consecutive treatments during a single week.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hypoxia during maintenance hemodialysis-the critical role of pH.
McGuire S, Krishnan N, Malik AR, Waddell A, et al · · 2023 · cited 1× · PMID 36755842 · DOI 10.1093/ckj/sfac191
Verify or expand the search:
- PubMed search for NCT04501159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Renal Disease on Dialysis
Currently open trials in the same condition.
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT07016841 — Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins · recruiting
- NCT05654103 — Comparing Surgical and Endovascular Arteriovenous Fistula Creation · NA · recruiting
- NCT06483074 — Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients · Phase 2 · recruiting
- NCT06249932 — Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease · Phase 4 · recruiting
Other Coventry University trials
Trials by the same sponsor.
- NCT06377319 — Decision Support System for Diagnosis and Progression of Heart Failure · not yet recruiting
- NCT05409404 — The Effects of 8 Weeks Post Exercise Hot Water Immersion on Vascular and Cardiometabolic Health in Physically Inactive M · NA · completed
- NCT05059899 — Home-based Circuit Training for People With Intermittent Claudication · NA · completed
- NCT05492552 — Cardiovascular Function and Physical Activity in COVID-19 · NA · completed
- NCT05292287 — Remote Maintenance Cardiac Rehabilitation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04501159 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Coventry University
- Last refreshed: 30 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04501159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing